Onchocerciasis (river blindness): larva-induced eczema (onchodermatitis) from an important oculocutaneous tropical disease spilling over into North America and Europe.
暂无分享,去创建一个
[1] D. McFarland,et al. Economic evaluations of onchocerciasis interventions: a systematic review and research needs , 2019, Tropical medicine & international health : TM & IH.
[2] P. Preux,et al. Comprehensive management of epilepsy in onchocerciasis-endemic areas: lessons learnt from community-based surveys , 2019, Infectious Diseases of Poverty.
[3] A. Laudisoit,et al. High prevalence of epilepsy in an onchocerciasis endemic health zone in the Democratic Republic of the Congo, despite 14 years of community-directed treatment with ivermectin: A mixed-method assessment , 2019, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[4] T. Geary,et al. Flubendazole as a macrofilaricide: History and background , 2019, PLoS neglected tropical diseases.
[5] M. Boussinesq,et al. Epidemiology of onchocerciasis-associated epilepsy in the Mbam and Sanaga river valleys of Cameroon: impact of more than 13 years of ivermectin , 2018, Infectious Diseases of Poverty.
[6] R. Idro,et al. The natural history of nodding syndrome. , 2018, Epileptic disorders : international epilepsy journal with videotape.
[7] T. Nutman,et al. A Serological Survey of Human Onchocerciasis in Yemen. , 2018, The American journal of tropical medicine and hygiene.
[8] M. Vaillant,et al. Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial , 2018, The Lancet.
[9] K. Janda,et al. Noninvasive Urine Biomarker Lateral Flow Immunoassay for Monitoring Active Onchocerciasis , 2018, ACS infectious diseases.
[10] A. Laudisoit,et al. High prevalence of epilepsy in onchocerciasis endemic health areas in Democratic Republic of the Congo , 2018, Infectious Diseases of Poverty.
[11] J. Keiser,et al. Efficacy and tolerability of moxidectin alone and in co-administration with albendazole and tribendimidine versus albendazole plus oxantel pamoate against Trichuris trichiura infections: a randomised, non-inferiority, single-blind trial. , 2018, The Lancet. Infectious diseases.
[12] B. Boatin,et al. Is onchocerciasis elimination in Africa feasible by 2025: a perspective based on lessons learnt from the African control programmes , 2018, Infectious Diseases of Poverty.
[13] Solórzano Sánchez,et al. Elimination of onchocerciasis from Colombia: first proof of concept of river blindness elimination in the world , 2018, Parasites & Vectors.
[14] P. Preux,et al. Report of the first international workshop on onchocerciasis-associated epilepsy , 2018, Infectious Diseases of Poverty.
[15] D. Boakye,et al. Onchocerciasis in Yemen: moving forward towards an elimination program. , 2018, International health.
[16] M. Boussinesq,et al. Alternative treatment strategies to accelerate the elimination of onchocerciasis , 2018, International health.
[17] A. Hoerauf,et al. Validation of onchocerciasis biomarker N-acetyltyramine-O-glucuronide (NATOG) , 2017, Bioorganic & medicinal chemistry letters.
[18] S. Antinori,et al. Is imported onchocerciasis a truly rare entity? Case report and review of the literature. , 2017, Travel medicine and infectious disease.
[19] C. Hennequin,et al. Imported filariasis in Europe: A series of 31 cases from Metropolitan France. , 2017, European journal of internal medicine.
[20] D. Boakye,et al. Genome-wide analysis of ivermectin response by Onchocerca volvulus reveals that genetic drift and soft selective sweeps contribute to loss of drug sensitivity , 2016, bioRxiv.
[21] V. Cama,et al. Detection of Onchocerca volvulus in Skin Snips by Microscopy and Real-Time Polymerase Chain Reaction: Implications for Monitoring and Evaluation Activities. , 2016, The American journal of tropical medicine and hygiene.
[22] G. Weil,et al. Diagnostic Tools for Onchocerciasis Elimination Programs. , 2015, Trends in parasitology.
[23] W. Campbell. History of avermectin and ivermectin, with notes on the history of other macrocyclic lactone antiparasitic agents. , 2012, Current pharmaceutical biotechnology.
[24] A. Hoerauf,et al. Onchocerciasis: the Role of Wolbachia Bacterial Endosymbionts in Parasite Biology, Disease Pathogenesis, and Treatment , 2011, Clinical Microbiology Reviews.
[25] R. Schwartz,et al. Ivermectin: pharmacology and application in dermatology , 2005, International journal of dermatology.
[26] R. Schwartz,et al. Cutaneous onchocercoma , 2004, International journal of dermatology.
[27] W. Kipp,et al. Simulium neavei-transmitted onchocerciasis: HIV infection increases severity of onchocercal skin disease in a small sample of patients. , 2003, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[28] P. Pisella,et al. [Human onchocerciasis and "sowda" in the Republic of Yemen]. , 2001, Bulletin de l'Academie nationale de medecine.
[29] M. Ostrowski,et al. Filarial infections increase susceptibility to human immunodeficiency virus infection in peripheral blood mononuclear cells in vitro. , 2000, The Journal of infectious diseases.
[30] T. Nutman,et al. A rapid-format antibody card test for diagnosis of onchocerciasis. , 2000, The Journal of infectious diseases.
[31] M. Hagan. Onchocercal dermatitis: clinical impact. , 1998, Annals of tropical medicine and parasitology.
[32] D. Richard-Lenoble,et al. [Onchodermatitis (sowda) in patients in Yémen. Clinical and histologic course after treatment with ivermectin]. , 1997, Sante.
[33] M. Boussinesq,et al. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection , 1997, The Lancet.
[34] W. Kipp,et al. Onchocerciasis and human immunodeficiency virus in western Uganda: prevalences and treatment with ivermectin. , 1995, The American journal of tropical medicine and hygiene.
[35] Y. Al‐Qubati. The first use of ivermectin for the treatment of onchocerciasis in Yemen. , 1994, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[36] M. Murdoch,et al. A clinical classification and grading system of the cutaneous changes in onchocerciasis , 1993, The British journal of dermatology.
[37] R. Kapila,et al. Cutaneous Onchocerciasis , 1987, International journal of dermatology.
[38] W. Campbell,et al. Ivermectin: a potent new antiparasitic agent. , 1983, Science.
[39] M. Kerner,et al. Anthropophily of Simulium damnosum s.l. and its rôle as a vector of human onchocerciasis in the Yemen Arab Republic. , 1982, Tropenmedizin und Parasitologie.
[40] A. Fawdry. Onchocerciasis in South Arabia. , 1957, Transactions of the Royal Society of Tropical Medicine and Hygiene.